Yan A, Bryant E. Quinolones. StatPearls. Treasure Island: StatPearls Publishing; 2022.

Google Scholar 

Adriaenssens N, Bruyndonckx R, Versporten A, Hens N, Monnet DL, Molenberghs G, et al. Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017. J Antimicrob Chemother. 2021;76:30–6.

Article  Google Scholar 

Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44:161–4.

Article  PubMed  PubMed Central  Google Scholar 

Hopper D, Jacoby G. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;176:139–48.

Google Scholar 

European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance in the EU/EEA—a One Health response. 2022. https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-policy-brief-2022.pdf Accessed 4 Nov 2022.

Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin Ther. 2016;38:1930–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pino-Marín DE, Madrigal-Cadavid J, Amariles P. Clinical relevance of drug interactions with antibiotics related to changes in the absorption: structured review. Ces Med. 2018;32:235–49.

Article  Google Scholar 

Gregg CR. Drug interactions and anti-infective therapies. Am J Med. 1999;106:227–37.

Article  CAS  PubMed  Google Scholar 

Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1990;18:210–9.

Article  CAS  PubMed  Google Scholar 

Sulochana SP, Syed M, Chandrasekar DV, Mullangi R, Srinivas NR. Clinical drug–drug pharmacokinetic interaction potential of sucralfate with other drugs: review and perspectives. Eur J Drug Metab Pharmacokinet. 2016;41:469–503.

Article  CAS  PubMed  Google Scholar 

Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros. 2006;5:153–7.

Article  CAS  PubMed  Google Scholar 

Mallet L, Huang A. Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient. Ann Pharmacother. 2005;39:150–2.

Article  PubMed  Google Scholar 

Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. Antimicrob Agents Chemother. 2020;64:e02167-e2219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiesner A, Zagrodzki P, Paśko P. Do dietary interventions exert clinically important effects on the bioavailability of beta-lactam antibiotics? A systematic review with meta-analyses. J Antimicrob Chemother. 2024;79:722–57.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1–8.

Google Scholar 

Higgins JPT, Li T, Sterne JAC. Revised Cochrane risk of bias tool for randomized trials (RoB 20): Additional considerations for crossover trials. Cochrane Methods. 2021;1–6.

NIH. Study quality assessment tools. 2022. https://www.nhlbi.nih.gov/health‐topics/study‐quality‐assessment‐tools Accessed 25 Jun 2022.

Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales. Stat Med. 2008;27:6072–92.

Article  PubMed  PubMed Central  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

Article  PubMed  PubMed Central  Google Scholar 

Deeks J, Higgins J, Altman D. Chapter 10: Analysing data and undertaking meta-analyses. In: Cochrane Handb Syst Rev Interv version 63. 2022.

Ohnishi A, Toyoki T, Yoshikawa K, Hashizume K, Tanigawa T, Tanaka T, et al. Safety, pharmacokinetics and influence on the intestinal flora of BAY 12–8039 (moxifloxacin hydrochloride) after oral administration in healthy male subjects. Jpn Pharmacol Ther. 2005;33:1029–45.

CAS  Google Scholar 

Zhang J, Zhang Y-Y, Shi Y-G, Yu J-C, Wang L. Clinical pharmacokinetic study on ciprofloxacin. Chin Pharmacol Bull. 1996;12:430–3.

CAS  Google Scholar 

FDA. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf Accessed 1 Jul 2022.

Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm Drug Res. 2009;66:587–604.

CAS  Google Scholar 

Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: clinical efficacy and safety. Am J Heal Pharm. 2001;58:379–88.

Article  CAS  Google Scholar 

Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101–19.

Article  CAS  PubMed  Google Scholar 

Blokhina SV, Sharapova AV, Ol’khovich MV, Volkova TV, Perlovich GL. Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. Eur J Pharm Sci. 2016;93:29–37.

Article  CAS  PubMed  Google Scholar 

Wiesner A, Skrońska M, Gawlik G, Marcinkowska M, Zagrodzki P, Paśko P. Interactions of antiretroviral drugs with food, beverages, dietary supplements, and alcohol—a systematic review and meta-analysis. AIDS Behav. 2023;27:1441–68.

Article  PubMed  Google Scholar 

Wiesner A, Gajewska D, Paśko P. Levothyroxine interactions with food and dietary supplements—a systematic review. Pharmaceuticals. 2021;14:206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2:294.

Article  CAS  PubMed  Google Scholar 

Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrobal Agents Chemother. 1991;35:1004–7.

Article  CAS  Google Scholar 

Lomaestro BM, Bailie GR. Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother. 1993;27:1325–8.

Article  CAS  PubMed  Google Scholar 

Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36:830–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walden DM, Khotimchenko M, Hou H, Chakravarty K, Varshney J. Effects of magnesium, calcium, and aluminum chelation on fluoroquinolone absorption rate and bioavailability: a computational study. Pharmaceutics. 2021;13:594.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW. Lack of bioequivalence 4f ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42:461–6.

CAS  PubMed  Google Scholar 

Sultana R, Ullah A, Akbor MM, Azad MAK, Latif AHMM, Hasnat A. Effect of orange juice on bioavailability of levofloxacin. J Appl Res. 2008;8:34–42.

CAS  Google Scholar 

Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol. 2003;43:539–44.

CAS  PubMed  Google Scholar 

Park MS, Okochi H, Benet LZ. Is ciprofloxacin a substrate of P-glycoprotein? Arch Drug Inf. 2011;4:1–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cravens MG, Sherman N, Sawaya J. Ciprofloxacin-induced Stevens–Johnson syndrome with grapefruit juice consumption: a case report. Cureus. 2019;11: e3827.

PubMed  PubMed Central  Google Scholar 

Matsumoto F, Sakurai I, Imai T, Ishida Y, Takahashi T, Morita M, et al. Fundamental and clinical studies on pazufloxacin. Jpn J Chemother. 1995;43:244–56.

CAS  Google Scholar 

Staib AH, Stille W, Dietlein G, Shah PM, Harder S, Mieke S, et al. Interaction between quinolones and caffeine. Drugs. 1987;34:170–4.

Article  CAS  PubMed  Google Scholar 

Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1989;33:474–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45:234–40.

Article  CAS  PubMed  Google Scholar 

Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1991;35:660–4.

Article  CAS  PubMed  PubMed Central  Google Scholar